Cambrex, an East Rutherford, New Jersey-based contract manufacturer of small-molecule active pharmaceutical ingredients, has installed multiple continuous flow reactor platforms at its High Point, North Carolina facility.

The investment aims to reinforce the company’s existing experience in continuous flow. This latest investment in continuous flow will focus on the development of processes to supply clinical as well as commercial demand for chemical syntheses.

The investment in developmental capabilities builds upon the recent expansions made by the company at commercial-scale in the continuous flow production unit, at its Karlskoga, Sweden facility, which is capable of producing multiple metric tons of high purity intermediates per annum.

The continuous-flow development center is the latest investment at Cambrex’s High Point site, which has recently seen the completion and qualification of a new 11,000-square-foot analytical laboratory and a 400-square-foot pilot-plant expansion with a reactor capacity of 4,000 liters.

Source: Cambrex